Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK

Leukemia

Volumn 24, Issue 9, 2010, Pages 1617-1630

  Ng, Y Y ^a,b   Baert, M R M ^a,b   Pike Overzet, K ^a,b   Rodijk, M ^a,b   Brugman, M H ^c   Schambach, A ^c   Baum, C ^c   Hendriks, R W ^a   Van Dongen, J J M ^a   Staal, F J T ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

B cells; BTK; gene therapy; lentivirus; stem cells; XLA

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; LENTIVIRUS VECTOR; T LYMPHOCYTE ANTIGEN; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CALCIUM; CODON; PRIMER DNA; PROTEIN TYROSINE KINASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CALCIUM MOBILIZATION; CELL PROLIFERATION; CODON USAGE; CONTROLLED STUDY; ENGRAFTMENT; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PERITONEAL CAVITY; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS EXPRESSION; WILD TYPE; X LINKED AGAMMAGLOBULINEMIA; ANIMAL; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CODON; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; KNOCKOUT MOUSE; LENTIVIRINAE; METABOLISM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

ANIMALS; B-LYMPHOCYTES; BASE SEQUENCE; BONE MARROW TRANSPLANTATION; CALCIUM; CODON; DNA PRIMERS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTAGENESIS, INSERTIONAL; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; TRANSDUCTION, GENETIC;

EID: 77956428092     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.140     Document Type: Article

References (58)

1. Fischer A. Human primary immunodeficiency diseases: a perspective. Nat Immunol 2004; 5: 23-30.
2. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 2007; 117: 1456-1465.
3. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007; 15: 1910-1916.
4. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361: 226-233.
5. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993; 72: 279-290.
6. Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001; 23: 436-446.
7. Mangla A, Khare A, Vineeth V, Panday NN, Mukhopadhyay A, Ravindran B et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 2004; 104: 1191-1197.
8. Schmidt U, Boucheron N, Unger B, Ellmeier W. The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 2004; 134: 65-78.
9. Whyburn LR, Halcomb KE, Contreras CM, Lowell CA, Witte ON, Satterthwaite AB. Reduced dosage of Brutons tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. J Immunol 2003; 171: 1850-1858.
10. de Weers M, Verschuren MC, Kraakman ME, Mensink RG, Schuurman RK, van Dongen JJ et al. The Brutons tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 1993; 23: 3109-3114.
11. de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW. Mutation analysis of the Brutons tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum Mol Genet 1994; 3: 161-166.
12. Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS et al. Expression of Brutons agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994; 152: 557-565.
13. von Lindern M, Schmidt U, Beug H. Control of erythropoiesis by erythropoietin and stem cell factor: a novel role for Brutons tyrosine kinase. Cell Cycle 2004; 3: 876-879.
14. Aoki Y, Isselbacher KJ, Cherayil BJ, Pillai S. Tyrosine phosphorylation of Blk and Fyn Src homology 2 domain-binding proteins occurs in response to antigen-receptor ligation in B cells and constitutively in pre-B cells. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 4204-4208.
15. Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptorligated B cells. Proc Natl Acad Sci USA 1994; 91: 10606-10609.
16. Lindvall JM, Blomberg KE, Valiaho J, Vargas L, Heinonen JE, Berglof A et al. Brutons tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005; 203: 200-215.
17. Noordzij JG, de Bruin-Versteeg S, Hartwig NG, Weemaes CM, Gerritsen EJ, Bernatowska E et al. XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts. J Clin Immunol 2002; 22: 306-318.
18. van Zelm MC, Geertsema C, Nieuwenhuis N, de Ridder D, Conley ME, Schiff C et al. Gross deletions involving IGHM, BTK, or Artemis: a model for genomic lesions mediated by transposable elements. Am J Hum Genet 2008; 82: 320-332.
19. Noordzij JG, de Bruin-Versteeg S, Comans-Bitter WM, Hartwig NG, Hendriks RW, de Groot R et al. Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children. Pediatr Res 2002; 51: 159-168.
20. Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G et al. Defective B cell development and function in Btk-deficient mice. Immunity 1995; 3: 283-299.
21. Wicker LS, Scher I. X-linked immune deficiency (xid) of CBA/N mice. Curr Top Microbiol Immunol 1986; 124: 87-101.
22. Witkowski J, Forrester LM, Ansell JD, Micklem HS. Influence of the xid mutation on B lymphocyte development in adult mice. Adv Exp Med Biol 1985; 186: 47-55.
23. Middendorp S, Dingjan GM, Hendriks RW. Impaired precursor B cell differentiation in Brutons tyrosine kinase-deficient mice. J Immunol 2002; 168: 2695-2703.
24. Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T et al. Genetic analysis of patients with defects in early B-cell development. Immunol rev 2005; 203: 216-234.
25. Yu PW, Tabuchi RS, Kato RM, Astrakhan A, Humblet-Baron S, Kipp K et al. Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood 2004; 104: 1281-1290.
26. Ellmeier W, Jung S, Sunshine MJ, Hatam F, Xu Y, Baltimore D et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J Exp Med 2000; 192: 1611-1624.
27. Moreau T, Barlogis V, Bardin F, Nunes JA, Calmels B, Chabannon C et al. Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA. Gene Ther 2008; 15: 942-952.
28. Moreau T, Calmels B, Barlogis V, Michel G, Tonnelle C, Chabannon C. Potential application of gene therapy to X-linked agammaglobulinemia. Curr Gene Ther 2007; 7: 284-294.
29. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672. (Pubitemid 30241569)
30. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
31. Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008; 16: 590-598.
32. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007; 117: 2225-2232.
33. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
34. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
35. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-529.
36. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 2006; 103: 11730-11735.
37. Modlich U, Bohne J, SchmidtM, von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
38. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, Li Z et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008; 22: 1519-1528.
39. Hendriks RW, de Bruijn MF, Maas A, Dingjan GM, Karis A, Grosveld F. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. Embo J 1996; 15: 4862-4872.
40. Schambach A, Galla M, Maetzig T, Loew R, Baum C. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15: 1167-1173.
41. Werner M, Kraunus J, Baum C, Brocker T. B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element. Gene Ther 2004; 11: 992-1000.
42. Baum C, Itoh K, Meyer J, Laker C, Ito Y, Ostertag W. The potent enhancer activity of the polycythemic strain of spleen focusforming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J virol 1997; 71: 6323-6331.
43. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391-400.
44. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
45. Luis TC, Weerkamp F, Naber BA, Baert MR, de Haas EF, Nikolic T et al. Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. Blood 2009; 113: 546-554.
46. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354: 1901-1912.
47. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 2008; 8: 581-593.
48. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
49. Rohrer J, Conley ME. Correction of X-linked immunodeficient mice by competitive reconstitution with limiting numbers of normal bone marrow cells. Blood 1999; 94: 3358-3365.
50. Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E et al. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 2009; 16: 111-118.
51. Tanabe H, Miyake K, Shimada T. HIV-mediated expression of Btk in hematopoietic stem cells is not sufficient to restore B cell function in X-linked immunodeficient mice. J Nippon Med Sch 2005; 72: 203-212.
52. Sochorova K, Horvath R, Rozkova D, Litzman J, Bartunkova J, Sediva A et al. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood 2007; 109: 2553-2556.
53. Kersseboom R, Middendorp S, Dingjan GM, Dahlenborg K, Reth M, Jumaa H et al. Brutons tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in pre-B cells. J Exp Med 2003; 198: 91-98.
54. Maas A, Dingjan GM, Savelkoul HF, Kinnon C, Grosveld F, Hendriks RW. The X-linked immunodeficiency defect in the mouse is corrected by expression of human Brutons tyrosine kinase from a yeast artificial chromosome transgene. Eur J Immunol 1997; 27: 2180-2187.
55. Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Leukemia 2008; 22: 1849-1852.
56. Cavazzana-Calvo M, Andre-Schmutz I, Dal Cortivo L, Neven B, Hacein-Bey-Abina S, Fischer A. Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol 2009; 21: 544-548.
57. Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet 2008 371 2044-2047.
58. Kerns HM, Ryu BY, Stirling BV, Sather BD, Astrakhan A, Humblet- Baron S, Liggitt D, Rawlings DJ. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia Blood, e-pub ahead of print 21 January 2010